

Synthesis and antibacterial activity of sulfonamide derivatives at C-8 alkyl chain of anacardic acid mixture isolated from a natural product cashew nut shell liquid (CNSL)

N SUBHAKARA REDDY^{a,b}, A SRINIVAS RAO^a, M ADHARVANA CHARI^{c,d,*},
V RAVI KUMAR^a, V JYOTHY^c and V HIMABINDU^b

^aMedicinal chemistry Laboratory, GVK Biosciences Pvt Ltd, Plot No 5C, IDA, Uppal Road, Hyderabad 500 039, India

^bCentre for Environment, Institute of Science and Technology, JNT University, Kukatpally, Hyderabad 500 085, India

^cDr. MACS Bio-Pharma Pvt. Ltd., Plot-32/A, Westren Hills, Kukatpally, Hyderabad 500 085, India

^dDepartment of Complexity Science and Engineering, School of Frontier Sciences, 5-1-5, Kashiwanoha, Kashiwa, University of Tokyo, Chiba 277 8561, Japan
e-mail: drmac_s@yahoo.com

MS received 20 August 2011; revised 11 December 2011; accepted 26 December 2011

Abstract. Synthesis and antibacterial activity of some novel biologically active sulfonamide derivatives at C-8 alkyl chain of anacardic acid (**7a–7l**), prepared from commercially available anacardic acid mixture (**1a–d**). These compounds were tested for Gram positive and Gram negative bacterial cultures; most of the compounds showed higher antibacterial activity compared with standard drug ampicillin.

Keywords. Synthesis; sulfonamide derivatives; anacardic acid; antibacterial activity.

1. Introduction

In continuation of our ongoing investigation in the search of new bioactive compounds using non-isoprenoid phenolic lipids from *Anacardium occidentale* as starting material, we describe here the synthesis and biological activity of some novel sulfonamide derivatives at C-8 alkyl chain of anacardic acid mixture isolated from a natural product Cashew Nut Shell Liquid (CNSL). Anacardic acid mixture (**1a–d**) isolated from a natural product CNSL which is a by-product of cashew nut industry and these are salicylic acid derivatives with a non-isoprenoid alk(en)yl side chain.¹ Anacardic acid and its derivatives exhibit biological activities like antimicrobial activity^{2,3} and soybean lipoxygenase-1 inhibitory activity^{4,5} Reddy *et al.* reported the synthesis of benzamide derivatives of anacardic acid⁶ sildenafil analogues⁷ dihydropyridine analogues⁸ as calcium channel blockers, isonicotinoylhydrazones for antimycobacterial activity⁹ starting from anacardic acid. Kubo *et al.* reported the separation of anacardic acid into monoene (15:1), diene (15:2) and triene (15:3) by preparative high pressure liquid chromatography and

tested against cancer cells, and found to show moderate cytotoxic activity on BT-20 breast and HeLa epithelioid cervix carcinoma cells.¹⁰ Recently, a few anacardic acid derivatives exhibited various activities like affect of the structure of the enzyme,¹¹ anacardic acid is a specific activator of kinase activity of Aurora Kinase A,¹² suppresses expression of nuclear factor-kB regulated gene products leading to potentiation of apoptosis¹³ inhibitor of the HAT activity of recombinant *Plasmodium falciparum* GCN5¹⁴ and as modulators of histone acetyltransferases.¹⁵

The emergence of drug-resistant strains in clinical applications^{16–18} especially to gram positive bacteria^{19,20} has created a problem of global proportions.^{21,22} This phenomenon has led in creating novel antibacterial agents distinct from the existing classes of compounds. Anacardic acid (pentadecyl salicylic acid) is a phenolic constituent present in CNSL; (*Anacardium occidentale* L.) and exhibits antimicrobial properties^{2,3} which have led to the preparation of various analogues.^{23,24} Synthesis of lasiodiplodin from the non-isoprenoid phenolic lipids of CNSL as well as the salicylate macrolactone and other derivatives were reported by Santos *et al.*²⁵ The interesting chemical characteristics of anacardic acid, such as the presence of a double

*For correspondence

bond at the 8-position of the long-chain in the monoene, diene and triene components and a convenient aromatic system led us to search for a strategy to convert these materials into useful products. In the present work, we wish to report the synthesis of novel cell permeable sulfonamide compounds from abundantly and cheaply available anacardic acid which was a major constituent of CNSL natural source to evaluate their biological activity by various antibacterial strains. This report describes the synthesis, spectroscopic identification and antibacterial activity of some novel sulfonamide derivatives at C-8 alkyl chain of anacardic acid mixture against *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Streptococcus pyogenes* bacterial strains.

2. Experimental

2.1 General consideration

All chemicals and solvents were obtained from Aldrich and Spectrochem, India and used without further purification. Column chromatographic separations were carried out on silica gel 60–120 mesh size and eluting with a gradient of hexane: ethyl acetate. Analytical thin layer chromatography was performed on pre-coated Merck silica gel (60F254/0.2 mm) plates using UV light, 5% ethanolic phosphomolybdic acid or iodine vapours to visualize the spots. Melting points were determined in open glass capillaries on a Mel-temp apparatus and are uncorrected. The IR spectra were recorded on a Thermo Nicolet IR 200 FT-IR spectrometer as KBr pellets and the wave numbers were given in cm^{-1} . The ^1H and ^{13}C NMR spectra of samples were recorded on a Varian EM-360, NMR spectrometer using TMS as an internal standard in CDCl_3 . The mass spectra were recorded on Jeol JMS-D 300 and Finnigan Mat b at 70 eV with an emission current of 100 μA . The oxidative cleavages were performed with a Welsbach T-408 ozonizator and the catalytic hydrogenations in a Parr apparatus.

2.1a General procedure—Isolation of anacardic acids (1): The shells (500 g) of cashew nuts from *Anacardium occidentale* (Ceará, Brazil) were extracted in a Soxhlet extractor with commercial 95% ethanol (2.0 L) during 6 h, yielding a crude extract (CNSL, 157 g, 31% by weight). Anacardic acids (**1**) were removed in 61% from CNSL (15.25 g) either by precipitation with lead nitrate or calcium hydroxide according to protocols described in the literature.²⁶ The spectral properties were identical to those reported in the literature.^{26a}

2.1b Synthesis of methyl anacardate methyl ethers ene mixture (2): To a solution of compound **1** (65 g, 186.78 mmol) in acetone was added K_2CO_3 (103.1 g, 747.12 mmol), and di methyl sulfate (44.3 mL, 466.95 mmol). The contents were heated at 65°C for 5 h. Reaction mixture was cooled to room temperature, filtered and washed with ethyl acetate. Filtrate was distilled off, crude compound was re-dissolved in ethyl acetate (300 mL). Organic layer was washed with water, brine solution and dried over anhydrous sodium sulphate and distilled off ethyl acetate. Crude compound was purified by 60–120 silica pet ether pack column compound was eluted with 5% ethyl acetate: pet ether to get compound **2**, Yield: 58 g, nature of compound: light yellow liquid.

2.1c 2-(8-Hydroxy-octyl)-6-methoxy-benzoic acid methyl ester (3): A solution of **2** (15 g, 40.540 mmol) in dichloro methane: methanol (1:1, 500 mL) was cooled to -78°C and treated with a stream of O_3 gas until the completion of starting material. The reaction mixture was treated with the stream of O_2 at -78°C to remove excess amount of O_3 . To the reaction mixture was added to a solution of dimethyl sulfide (catalytic qty) at -78°C , and the mixture was allowed to stir at room temperature for 2 h. The reaction mixture was again cooled to -15°C , and was added sodium borohydride (9.97 g, 0.26 mol) portion-wise over a period of 45 min; the reaction mixture was allowed to reach room temperature and stirred for 18 h. To the reaction mixture, cold water was added (400 mL) and the aqueous layer was extracted with dichloromethane (2×200 mL). The combined organic layer was washed with brine solution (150 mL) dried over anhydrous sodium sulphate and concentrated. The residue was purified by neutral alumina column chromatography (eluted with 20% ethyl acetate: pet ether) to afford **3** as yellow liquid; Yield: 7.1 g (59.5%); IR (neat): ν_{max} 3401, 2930, 1728, 1586, 1467, 1268, 1110, 1071, 954, 749 cm^{-1} ; $^1\text{H-NMR}$ (400 MHz, CDCl_3): δ 1.31 (bs, 8H), 1.53–1.59 (m, 4H), 2.53 (t, 2H, $J = 8.0$ Hz), 3.63 (t, 2H, $J = 6.8$ Hz), 3.81 (s, 3H), 3.90 (s, 3H), 6.75 (d, 1H, $J = 8.4$ Hz), 6.82 (d, 1H, $J = 7.6$ Hz), 7.26–7.28 (m, 1H); ^{13}C NMR (100 MHz, CDCl_3), δ : 25.58, 29.16, 29.23, 29.63, 31.00, 32.62, 33.35, 52.10, 55.73, 62.81, 108.23, 121.37, 123.26, 130.18, 141.17, 156.10, 168.93; EI MS: m/z (Relative abundance %) 295 (M^+ , 100).

2.1d Synthesis of 2-(8-bromo-octyl)-6-methoxy-benzoic acid methyl ester (4): A solution of compound **3** (15 g, 51.02 mmol) in dichloro methane (150 mL) was added to dry pyridine (42 mL, 510.2 mmol) and tri phenyl

phosphene (22.73 g, 86.734 mmol) at 0°C. Carbon tetrabromide (25.4 g, 76.53 mmol) was added portion-wise over a period of 15 min. The mixture was slowly brought to room temperature and stirred for 6 h. Reaction mixture was diluted with DCM (100 mL) washed with 2N HCl (2 × 150 mL), water (200 mL), brine solution (175 mL), dried over anhydrous Na₂SO₄, filtered and evaporated under vacuum, Crude compound was purified by column chromatography using 10% ethyl acetate in pet ether to get pure compound **4** as yellow liquid; Yield: 16.5 g (90.8%); IR (DCM film): ν_{\max} 3071, 3002, 2931, 2854, 1732, 1588, 1464, 1437, 1268, 1109, 1072, 960, 749 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.29–1.42 (m, 8H), 1.52–1.59 (m, 2H), 1.80–1.87 (m, 2H), 2.53 (t, 2H, $J = 8.0$ Hz), 3.40 (t, 2H, $J = 7.2$ Hz), 3.82 (s, 3H), 3.90 (s, 3H), 6.76 (d, 1H, $J = 8.4$ Hz), 6.81 (d, 1H, $J = 7.6$ Hz), 7.24–7.28 (m, 1H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ 28.05, 28.56, 29.12, 29.26, 31.02, 32.72, 33.36, 34.02, 52.13, 55.78, 108.27, 121.39, 123.32, 130.20, 141.14, 156.14, 168.90 ppm; ESIMS (m/z): 357 (M+H)⁺. 359 (bromo).

2.1e Synthesis of 2-(8-aza-octyl)-6-methoxy-benzoic acid methyl ester (5): A solution of compound **4** (2.0 g, 5.617 mmol) in DMF (10 mL) was added to sodium azide (548 mg, 8.426 mmol). The mixture was heated at 100°C for 3 h, reaction mixture was poured into cool water (70 mL) and extracted with diethyl ether (2 × 40 mL), the organic layer was washed with water (50 mL), brine solution (30 mL), dried over anhydrous Na₂SO₄, filtered and evaporated under vacuum to obtain compound **5** as yellow liquid; Yield: 1.5 g (83.7%); IR (DCM film): ν_{\max} 3087, 3002, 2932, 2856, 2095, 1731, 1588, 1464, 1266, 1109, 1071, 753 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.30 (bs, 8H), 1.59 (brs, 4H), 2.53 (t, 2H, $J = 7.6$ Hz), 3.25 (t, 2H, $J = 7.2$ Hz), 3.82 (s, 3H), 3.91 (s, 3H), 6.76 (d, 1H, $J = 8.4$ Hz), 6.82 (d, 1H, $J = 8.0$ Hz), 7.25–7.29 (m, 1H) ppm; ESIMS (m/z): 320 (M+H)⁺.

2.1f Synthesis of 2-(8-Amino-octyl)-6-methoxy-benzoic acid methyl ester (6): A solution of compound **5** (2.0 g, mmol) in ethanol (30 mL) was taken into a 500 mL Parr-hydrogenation vessel and added a suspension of 10% Pd/C (220 mg, 10%) in 20 mL of ethanol under argon atmosphere and applied H₂-pressure (60 psi) for 2 h. Reaction mixture was filtered through celite bed and concentrated the filtrate under reduced pressure to obtain 2-(8-Amino-octyl)-6-methoxy-benzoic acid methyl ester (**6**) as a yellow liquid; Yield: 1.7 g (92.5%); IR (neat): ν_{\max} 3436, 2931,

2857, 1729, 1587, 1467, 1438, 1268, 1111, 1073, 829, 753 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.273 (brs, 8H), 1.54 (brs, 2H), 1.65–1.79 (m, 2H), 2.51 (t, 2H, $J = 7.6$ Hz), 2.94 (t, 2H, $J = 8.0$ Hz), 3.79 (s, 3H), 3.89 (s, 3H), 6.74 (d, 1H, $J = 8.0$ Hz), 6.80 (d, 1H, $J = 8.0$ Hz), 7.23–7.27 (m, 1H) ppm; ESIMS (m/z): 294 (M+H)⁺.

2.2 Synthesis of sulphonamides (7)

A solution of amine **6** (300 mg, 1.023 mmol) in dry dichloromethane (DCM) was added to triethyl amine (TEA) (2.55 mmol) followed by sulphonyl chlorides (1.22 mmol) at 0°C. The contents were slowly brought to room temperature and stirred for 2 h. Reaction mixture was diluted with DCM and washed with water and brine solution dried and distilled off and obtained crude compound was purified by column.

2.2a Synthesis of methyl 2-methoxy-6-(8-(methylsulfonamideo)octyl)benzoate (7a): Using **6** and methane sulphonyl chloride as starting materials, the title compound **7a** was obtained as a light yellow liquid; Yield: 96.5%; IR (neat): ν_{\max} 3294, 3087, 3009, 2932, 2856, 1728, 1667, 1588, 1464, 1434, 1320, 1268, 1151, 1107, 1072, 970, 826 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.29 (brs, 8H), 1.53–1.59 (m, 4H), 2.53 (t, 2H, $J = 7.8$ Hz), 2.95 (s, 3H), 3.09–3.14 (m, 2H), 3.82 (s, 3H), 3.91 (s, 3H), 4.23 (brs, 1H), 6.76 (d, 1H, $J = 8.8$ Hz), 6.81 (d, 1H, $J = 7.6$ Hz), 7.25–7.29 (m, 1H) ppm; ¹³C NMR (100 MHz, CDCl₃): δ 26.37, 28.84, 29.06, 29.14, 29.94, 30.90, 33.29, 39.99, 43.19, 52.08, 55.77, 108.33, 121.38, 123.34, 130.19, 141.09, 156.14, 168.89 ppm; MF: C₁₈H₂₉NO₅S; Exact Mass: 371.18; ESIMS (m/z): 372.1 (M+H)⁺.

2.2b Synthesis of methyl 2-methoxy-6-(8-(phenylsulfonamido)octyl)benzoate (7b): Using **6** and benzene sulphonyl chloride as starting materials, the title compound **7b** was obtained as a light pale yellow liquid; Yield: 90.2%; IR (neat): ν_{\max} 3288, 3064, 3003, 2932, 2856, 1726, 1588, 1459, 1322, 1268, 1162, 1099, 1078, 859 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.21 (brs, 8H), 1.41–1.45 (m, 2H), 1.51–1.56 (m, 2H), 2.52 (t, 2H, $J = 7.2$ Hz), 2.92–2.95 (m, 2H), 3.81 (s, 3H), 3.82 (s, 3H), 4.38 (s, 1H), 6.76 (d, 1H, $J = 8.4$ Hz), 6.80 (d, 1H, $J = 7.6$ Hz), 7.25–7.29 (m, 1H), 7.49–7.59 (m, 3H), 7.86 (d, 2H, $J = 7.6$ Hz) ppm; ¹³C NMR (100 MHz, CDCl₃): δ 26.7, 29.1, 29.2, 29.3, 29.6, 31.2, 36.2, 42.8, 51.5, 55.8, 111.4, 116.0, 120.3, 129.0, 130.3, 131.9, 136.8, 144.5, 156.3, 168.2 ppm; MF: C₂₃H₃₁NO₅S; Exact Mass: 433.19; ESIMS (m/z): 432.0 (M+H)⁺.

2.2c Synthesis of methyl 2-methoxy-6-(8-(2-methylphenyl sulfonamido) octyl) benzoate (7c): Using **6** and 2-methylphenylsulphonyl chloride as starting materials, the title compound **7c** was obtained as a yellow liquid; Yield: 74.4%; IR (neat): ν_{\max} 3304, 3061, 3007, 2932, 2855, 1728, 1588, 1464, 1431, 1318, 1270, 1158, 1112, 1073, 959, 755 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.18 (brs, 8H), 1.39–1.57 (m, 4H), 2.51 (t, 2H, $J = 7.6$ Hz), 2.64 (s, 3H), 2.89–2.94 (m, 2H), 3.82 (s, 3H), 3.90 (s, 3H), 4.42 (s, 1H), 6.75–6.81 (m, 2H), 7.25–7.32 (m, 3H), 7.42–7.46 (m, 1H), 7.95–7.97 (m, 1H) ppm; ^{13}C NMR (100 MHz, CDCl_3): 22.0, 26.7, 29.1, 29.2, 29.3, 29.6, 31.3, 36.2, 42.8, 51.5, 55.8, 111.4, 116.0, 120.3, 120.8, 129.7, 130.5, 131.8, 136.6, 136.8, 138.9, 146.9, 156.3, 168.2 ppm; MF: $\text{C}_{24}\text{H}_{33}\text{NO}_5\text{S}$; Exact Mass: 447.21; ESIMS (m/z): 448.1 (M+H) $^+$.

2.2d Synthesis of methyl 2-methoxy-6-(8-(methylphenylsulfonamido) octyl) benzoate (7d): Using **6** and para toluene sulphonyl chloride as starting materials, the title compound **7d** was obtained as a light yellow liquid; Yield: 98%; IR (neat): ν_{\max} 3285, 3050, 2931, 2856, 1728, 1589, 1464, 1436, 1322, 1269, 1157, 1104, 1076, 817 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.213 (brs, 8H), 1.39–1.60 (m, 4H), 2.42 (s, 3H), 2.51 (t, 2H, $J = 7.6$ Hz), 2.88–2.96 (m, 2H) 3.81 (s, 3H), 3.90 (s, 3H), 4.28 (s, 1H), 6.76 (d, 1H, $J = 8.4$ Hz), 6.80 (d, 1H, $J = 7.6$ Hz), 7.25–7.31 (m, 3H), 7.73 (d, 2H, $J = 8.4$ Hz) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 21.43, 26.37, 28.80, 29.06, 29.17, 29.45, 30.94, 33.34, 43.12, 52.10, 55.82, 108.35, 121.41, 123.4, 127.04, 129.6, 130.21, 136.99, 141.15, 143.21, 156.2, 168.9 ppm; MF: $\text{C}_{24}\text{H}_{33}\text{NO}_5\text{S}$; Exact Mass: 447.21; ESIMS (m/z): 446.1 (M-H) $^+$.

2.2e Synthesis of methyl 2-(8-(2,5-dimethylphenylsulfonamido) octyl)-6-methoxybenzoate (7e): Using **6** and 2,5-dimethylphenylsulphonyl chloride as starting materials, the title compound **7e** was obtained as a yellow liquid; Yield: 74.1%; IR (neat): ν_{\max} 3305, 3066, 3013, 2932, 2856, 1728, 1589, 1464, 1429, 1317, 1268, 1151, 1105, 1073, 967, 896 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.19 (brs, 8H), 1.39–1.44 (m, 2H), 1.50–1.57 (m, 2H), 2.36 (s, 3H), 2.52 (t, 2H, $J = 7.6$ Hz), 2.58 (s, 3H), 2.87–2.93 (q, 2H), 3.82 (s, 3H), 3.90 (s, 3H), 4.40 (bs, 1H), 6.75–6.81 (m, 2H), 7.17–7.19 (m, 1H), 7.23–7.288 (m, 2H), 7.78 (s, 1H) ppm; MF: $\text{C}_{25}\text{H}_{35}\text{NO}_5\text{S}$; Exact Mass: 461.22; ^{13}C NMR (100 MHz, CDCl_3): 21.3, 22.0, 26.7, 29.1, 29.2, 29.3, 29.6, 31.2, 36.2, 42.8, 51.5, 55.8, 111.4, 116.0, 120.3,

126.6, 129.2, 132.1, 133.6, 135.7, 136.8, 138.8, 146.9, 156.3, 168.2 ppm; ESIMS (m/z): 462.1 (M+H) $^+$.

2.2f Synthesis of methyl 2-(8-(2,5-dichlorophenylsulfonamido) octyl)-6-methoxybenzoate (7f): Using **6** and 2,5-dichloro phenyl sulphonyl chloride as starting materials, the title compound **7f** was obtained as a pale yellow liquid; Yield: 60.4%; IR (neat): ν_{\max} 3310, 3085, 3008, 2932, 2856, 1726, 1586, 1456, 1334, 1268, 1164, 1101, 1078, 959, 894 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.22 (brs, 8H), 1.43–1.56 (m, 4H), 2.52 (t, 2H, $J = 7.2$ Hz), 2.91–2.96 (m, 2H), 3.82 (s, 3H), 3.91 (s, 3H), 4.96 (brs, 1H), 6.75–6.82 (m, 2H), 7.26–7.29 (m, 1H), 7.46 (brs, 2H), 8.09 (s, 1H) ppm; ^{13}C NMR (100 MHz, CDCl_3): δ 26.30, 28.75, 29.06, 29.16, 29.25, 29.30, 29.39, 30.93, 33.34, 43.32, 52.12, 55.82, 108.37, 121.41, 123.41, 129.47, 130.23, 131.09, 132.59, 133.42, 133.46, 138.72, 141.13, 156.22, 168.91 ppm; MF: $\text{C}_{23}\text{H}_{29}\text{Cl}_2\text{NO}_5\text{S}$; Exact Mass: 501.11; ESIMS (m/z): 500.0 (M-H) $^+$. 502.0 (chloro).

2.2g Synthesis of methyl 2-methoxy-6-(8-(phenylmethylsulfonamido) octyl) benzoate (7g): Using **6** and phenylmethylsulphonyl chloride as starting materials, the title compound **7g** was obtained as a pale yellow liquid; Yield: 26.8%; IR (neat): ν_{\max} 3294, 3072, 3034, 2931, 2856, 1727, 1667, 1587, 1461, 1320, 1268, 1147, 1117, 1074, 957 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.24 (brs, 8H) 1.34–1.56 (m, 4H), 2.53 (t, 2H, $J = 7.6$ Hz), 2.94–2.99 (m, 2H), 3.82 (s, 3H), 3.90 (s, 3H), 4.00 (s, 3H), 4.25 (s, 2H), 6.76 (d, 1H, $J = 8.4$ Hz), 6.81 (d, 1H, $J = 7.6$ Hz), 7.3 (m, 1H), 7.38 (brs, 5H) ppm; ^{13}C NMR (100 MHz, CDCl_3): 26.7, 29.1, 29.2, 29.3, 29.6, 31.2, 36.2, 43.2, 51.5, 55.8, 66.0, 111.4, 116.0, 120.3, 125.7, 128.6, 130.8, 133.2, 136.8, 146.9, 156.3, 168.2 ppm; MF: $\text{C}_{24}\text{H}_{33}\text{NO}_5\text{S}$; Exact Mass: 447.21; ESIMS (m/z): 446.1 (M-H) $^+$.

2.2h Synthesis of methyl 2-methoxy-6-(8-(naphthalene-2-sulfonamido) octyl) benzoate (7h): Using **6** and naphthalene-2-sulphonyl chloride as starting materials, the title compound **7h** was obtained as a light yellow liquid; Yield: 82.9%; IR (neat): 3286, 3056, 2929, 2855, 1726, 1587, 1511, 1461, 1323, 1268, 1156, 1111, 1074, 960, 903 cm^{-1} ; ^1H NMR (400 MHz, CDCl_3): δ 1.187 (broad singlet, 8H), 1.42–1.52 (m, 4H), 2.49 (t, 2H, $J = 7.6$ Hz), 2.95–2.99 (m, 2H), 3.82 (s, 3H), 3.89 (s, 3H), 4.45 (brs, 1H), 6.75–6.80 (m, 2H), 7.24–7.28 (m, 1H), 7.59–7.66 (m, 2H), 7.82–8.02 (m, 4H), 8.44 (s, 1H) ppm; MF: $\text{C}_{27}\text{H}_{33}\text{NO}_5\text{S}$; Exact Mass: 483.21; ^{13}C NMR (100 MHz, CDCl_3): 26.7, 29.1, 29.2,

29.3, 29.6, 31.2, 36.2, 42.8, 51.8, 55.8, 111.4, 116.0, 120.3, 123.4, 126.0, 126.2, 128.1, 129.4, 134.1, 136.7, 137.0, 146.9, 156.3, 168.2 ppm; ESIMS (m/z): 482.0 (M-H)⁺.

2.2i Synthesis of methyl 2-methoxy-6-(8-(thiophene-2-sulfonamido) octyl) benzoate (7i): Using **6** and thiophene-2- sulphonyl chloride as starting materials, the title compound **7i** was obtained as a light yellow liquid; Yield: 68.9%; IR (neat): ν_{\max} 3285, 3099, 2931, 2856, 1726, 1586, 1463, 1426, 1331, 1269, 1157, 1108, 1073, 1018, 728 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.23 (brs, 8H), 1.44–1.56 (m, 4H), 2.52 (t, 2H, *J* = 7.6 Hz), 3.00–3.05 (m, 2H), 3.82 (s, 3H), 3.91 (s, 3H), 4.46 (brs, 1H), 6.76 (d, 1H, *J* = 8.4 Hz), 6.81 (d, 1H, *J* = 8 Hz), 7.07–7.09 (m, 1H), 7.25–7.29 (m, 1H), 7.57–7.60 (m, 2H) ppm; ¹³C NMR (100 MHz, CDCl₃): 26.7, 29.1, 29.2, 29.3, 29.6, 31.2, 36.2, 42.9, 51.8, 55.8, 111.4, 116.0, 120.3, 125.8, 126.0, 127.2, 136.8, 146.9, 156.3, 168.2 ppm; MF: C₂₁H₂₉NO₅S₂; Exact Mass: 439.15; ESIMS (m/z): 438.0 (M-H)⁺.

2.2j Synthesis of methyl 2-(8-(5-bromo-thiophene-2-sulfonamido)octyl)-6-methoxy-benzoate (7j): Using **6** and 5-bromo thiophene-2- sulphonyl chloride as starting materials, the title compound **7j** was obtained as a light yellow liquid; Yield: 69.9%; IR (neat): ν_{\max} 3282, 3097, 2931, 2856, 1726, 1664, 1586, 1463, 1411, 1333, 1268, 1156, 1075, 1023, 966, 805 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.25 (brs, 8H), 1.45–1.56 (m, 4H), 2.53 (t, 2H, *J* = 7.6 Hz), 2.99–3.05 (m, 1H), 3.82 (s, 3H), 3.91 (s, 3H), 4.52 (s, 1H), 6.76 (d, 1H, *J* = 8.4 Hz), 6.81 (d, 1H, *J* = 7.6 Hz), 7.06 (d, 1H, *J* = 4 Hz), 7.26–7.29 (m, 1H), 7.35 (d, 1H, *J* = 4 Hz) ppm; ¹³C NMR (100 MHz, CDCl₃): 26.7, 29.1, 29.2, 29.3, 29.6, 31.2, 36.2, 42.9, 51.8, 55.8, 111.4, 111.9, 116.0, 120.3, 128.0, 128.7, 130.3, 136.8, 146.9, 156.3, 168.2 ppm; MF: C₂₁H₂₈BrNO₅S₂; Exact Mass: 517.06; ESIMS (m/z): 517.9 (M+H)⁺. 519.9 (bromo).

2.2k Synthesis of methyl 2-(8-(1-(5-fluoropyridin-2-yl)-1H-pyrazole-5-sulfonamido)octyl)-6-methoxybenzoate (7k): Using **6** and 1-(5-fluoropyridin-2-yl)-1H-pyrazole-5-sulphonyl chloride as starting materials, the title compound **7k** was obtained as a off-white solid; Yield: 93.7%; MP: 76–77°C; IR (neat): ν_{\max} 3234, 3119, 3069, 3002, 2941, 2856, 1725, 1583, 1511, 1445, 1325, 1275, 1180, 1152, 1131, 1085 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.24 (brs, 8H), 1.47–1.52 (m, 4H), 2.51 (t, 2H, *J* = 8.0 Hz), 3.00–3.05 (q, 2H), 3.81 (s, 3H), 3.90 (s, 3H), 4.49 (s, 1H), 6.74–6.82

(m, 2H), 7.24–7.28 (m, 1H), 7.56–7.61 (m, 1H), 7.95 (s, 1H), 7.99–8.02 (m, 1H), 8.288 (s, 1H), 8.88 (s, 1H) ppm; ¹³C NMR (100 MHz, CDCl₃): 26.7, 29.1, 29.2, 29.3, 29.6, 31.2, 36.2, 42.9, 51.8, 55.8, 110.9, 111.4, 113.3, 116.0, 120.3, 121.1, 134.5, 136.8, 139.8, 146.9, 147.6, 154.5, 156.3, 168.2 ppm; MF: C₂₅H₃₁FN₄O₅S; Exact Mass: 518.20; ESIMS (m/z): 517.1 (M-H)⁺.

2.2l Synthesis of methyl 2-(8-(1-(4-fluorophenyl)-1H-pyrazole-5-sulfonamido) octyl) -6-methoxybenzoate (7l): Using **6** and 1-(4-fluorophenyl)-1H-pyrazole-5-sulphonyl chloride as starting materials, the title compound **7l** was obtained as a pale brown liquid; Yield: 70.8%; IR (KBr pellet): ν_{\max} 3284, 3128, 3080, 3004, 2932, 2856, 1726, 1587, 1521, 1435, 1323, 1270, 1171, 1146, 1102, 1073, 954, 837 cm⁻¹; ¹H NMR (400 MHz, CDCl₃): δ 1.26 (brs, 8H), 1.45–1.56 (m, 4H), 2.52 (t, 2H, *J* = 7.2 Hz), 3.01–3.05 (q, 2H), 3.82 (s, 3H), 3.90 (s, 3H), 4.5 (s, 1H), 6.75–6.81 (m, 2H), 7.16–7.26 (m, 3H), 7.63–7.67 (m, 2H), 7.95 (s, 1H), 8.26 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): 26.7, 29.1, 29.2, 29.3, 29.6, 31.2, 36.2, 42.9, 51.8, 55.8, 111.4, 113.5, 115.6, 116.1, 120.3, 132.7, 135.3, 136.8, 141.9, 146.9, 156.3, 160.4, 168.2 ppm; MF: C₂₆H₃₂FN₃O₅S; Exact Mass: 517.20; ESIMS (m/z) ppm: 518.3 (M+H)⁺.

2.3 Antibacterial bioassay

Sulfonamide derivatives of anacardic acid (**7a–7l**) were dissolved in dimethyl sulphoxide at 250 µg/mL concentration. The composition of nutrient agar medium was bactotryptone (10 g), yeast extract (5 g), NaCl (10 g), final pH 7.4. After 18 h the exponentially growing cultures of the six bacteria in nutrient broth at 37°C were diluted in sterile broth. From each of these diluted cultures, 1 mL was added to 100 mL sterilized and cooled nutrient agar media to give a final bacterial count of 1 × 10⁶ cell/ml. The plates were set at room temperature and later dried at 37°C for 20 h. Paper discs (6 mm, punched from Whatmann No. 41 paper) were ultraviolet sterilized and used for the assays. Discs were soaked in different concentration of the test solution and placed on the inoculated agar media at regular intervals of 6–7 cm, care was taken to ensure that excess solution was not on the discs. All the samples were taken in triplicates. The plates were incubated at 37°C in an inverted fashion. Activity was determined by zones showing complete inhibition (mm). Growth inhibition was calculated with reference to positive control.

3. Results and discussion


We described here the synthesis of various biologically active novel sulfonamide derivatives at C-8 alkyl chain using anacardic acid mixture as starting material and various reagents in the given below conditions (scheme 1).

As shown in scheme 1, the heterogeneous mixture of anacardic acids (1)(**1a–d**) was isolated from commercially available CNSL by a reported method.²⁶ Accordingly, CNSL was treated with calcium hydroxide, during which anacardic acid present in CNSL becomes calcium anacardate, which was isolated and hydrolysed with diluted hydrochloric acid to generate anacardic acid ene mixture, which was a mixture of monoene, diene and triene located at (8', (8', 11') and (8', 11', 14') of the C15 alkyl chain, respectively. The mixture of anacardic acids (**1**) was quantitatively converted into **2**, on a multigram scale, by treatment with dimethyl sulphate under phase transfer catalysis. The mixture of dialkylated anacardic acids was submitted to ozonolysis, followed by reductive cleavage of the derived ozonides with sodium borohydride, furnishing the alcohol **3**. The resultant alcohol compound **3** was further converted to bromo compound **4** by treatment with CBr₄ in the presence of pyridine and TPP in CH₂Cl₂ at 0°C at room temperature for 8 h. Resultant bromo compound **4** was reacted with sodium azide followed by

reduction with Pd/C under H₂ pressure to obtain amine compound **6**, which was coupled with various sulfonyl chlorides in the presence of triethylamine in DCM to obtain compounds (**7a–7l**, scheme 1) of sulfonamide derivatives at C-8 alkyl chain were purified by column chromatography to yield title compounds. The structure of sulfonamide derivatives (**7a–7l**) was determined by using different spectroscopic techniques IR, ¹H NMR and Mass. The resulting compounds were screened for their antibacterial activity.













3.1 Biological activity

The sulfonamide derivatives (**7a–7l**) were screened for their antibacterial activity²⁷ against some of the pathogenic bacteria viz. *E. coli* (MTCC443), *P. aeruginosa* (MTCC424), *S. aureus* (MTCC96) and *S. pyogenes* (MTCC443) using agar well diffusion method according to the literature protocol.²⁶ The antibacterial activity of the analogues was compared with standard drug ampicilline and the results of investigation have been presented in table 1. It is observed that the most of the compounds showed high biological activity. Based on the test results, it is evident that several of synthesized anacardic acid analogues possess moderate to good activity against the *gram +ve* and *gram -ve* bacteria. Of all the compounds prepared, entities



Scheme 1. Synthesis of various biologically active sulfonamides from anacardic acid mixture. *Reagents:* (a) di methyl sulfate, K₂CO₃, ACN, 90°C, 24 h; (b) ozonolysis, MeOH, CH₂Cl₂, -78°C, 6 h; (c) MeOH, NaBH₄, 18 h, 0°C, R.T; (d) CBr₄, Pyridine, TPP, CH₂Cl₂, 0°C, R.T, 8 h; (e) NaN₃, DMF, 100°C, 4 h; (f) 10% Pd/C, 50 psi, 2 h; (g) different sulphonyl chlorides, TEA, DCM.

Table 1. Antibacterial activity of sulfonamide derivatives of anacardic acid (**7a–7l**).

S. No.	R ₁	Name of the bacteria (Conc. 250 µg/ml) and inhibition zone in mm			
		<i>E. coli</i> MTCC443	<i>P. aeruginosa</i> MTCC424	<i>S. aureus</i> MTCC96	<i>S. pyogenes</i> MTCC442
7a		19	18	16	16
7b		18	17	15	17
7c		20	18	17	17
7d		22	20	17	18
7e		17	22	17	19
7f		21	19	17	17
7g		20	19	16	18
7h		19	18	18	18
7i		22	19	16	16
7j		23	21	17	18
7k		21	19	17	17
7l		19	20	17	17
SD* ampicilline	SD* ampicilline	20	20	18	19

Standard indicated by star

7d, **7f**, **7g**, **7i**, **7j** and **7k**, of *E. coli* MTCC443, **7d**, **7e**, **7j** and **7l** of *P. aeruginosa* MTCC424, **7h**, **7k** and **7l** of *S. aureus* MTCC96 and **7e**, **7g**, and **7h** of *S. pyogenes* MTCC442 displayed good to excellent activity while the remaining compounds showed moderate activity. The most active antibacterial agent against *Escherichia*

coli found to be compound **7i** and **7j** having thiophene compound and other compounds in the series exhibited moderate to good activity. The activity depends on the R substituent to some extent, however all the compounds show antibacterial activity. So, other functionalities in the molecule will contribute to the activity as well. It

may be suggested that the anacardic acid derivative with a suitable R may lead to a good antibacterial agent against all the *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus* and *Streptococcus pyogenes* bacterial strains.

4. Conclusion

In summary, the present study describes a convenient and efficient protocol for the synthesis of sulfonamide derivatives by using anacardic acid mixture using various reagents and different conditions. We believe that this procedure is convenient, economic and a user-friendly process for the synthesis of these various sulphonamide compounds from anacardic acid mixture. All compounds structures were supported by IR, NMR, Mass spectral data. Sulphonamide derivatives were screened for their antibacterial activity against few bacterial strains and it was observed that some of the compounds showed more biological activity.

Acknowledgements

We thank GVK Biosciences Private Limited for the financial support and encouragement. We also thank the Analytical Department for their analytical data and to Dr. Balaram Patro for his helpful suggestions.

References

1. Tyman J H P 1979 *Chem. Soc. Rev.* **8** 499
2. Kubo I, Muroi H, Himejima M and Yamigiwa Y 1993 *J. Agric. Food Chem.* **41** 1016
3. Gillerman J L, Walsh N J, Werner N K and Schlenk H 1969 *Can. J. Microbiol.* **15** 1219
4. Shoba S V, Ramadoss C S and Ravindranath B 1994 *J. Nat. Prod.* **57** 1755
5. Ha T J and Kubo I 2005 *J. Agric. Food Chem.* **53** 4350
6. Chandregowda V, Kush A and Reddy G 2009 *Eur. J. Med. Chem.* **44** 2711
7. Paramashivappa R, Phanikumar P, Subba Rao P V and Srinivasa Rao A 2002 *J. Agric. Food Chem.* **50** 7709
8. Phanikumar P, Stotz S C, Paramashivappa R, Beedle M, Zamponi G W and Srinivasa Rao A 2002 *Mol. Pharmacol.* **61** 649
9. Narayana Swamy B, Suma T K, Venkateswara Rao G and Chandrasekara Reddy G 2007 *Eur. J. Med. Chem.* **42** 422
10. Kubo I, Ochi M, Viera P C and Komatsu S 1993 *J. Agric. Food Chem.* **41** 1012
11. Mantelingu K, Kishore A H, Balasubramanyam K, Kumar G V, Altaf M, Swamy S N, Selvi R, Das C, Narayana C, Rangappa K S and Kundu T K 2007 *J. Phys. Chem. B* **111** 4527
12. Hari Kishore A, Vedamurthy B M, Mantelingu K, Agrawal S, Ashok Reddy B A, Roy S, Rangappa K S and Kundu T K 2008 *J. Med. Chem.* **51** 792
13. Sung B, Pandey M K, Ahn K S, Yi T, Chaturvedi M M, Liu M and Aggarwal B 2008 *Blood* **111** 4880
14. Cui L, Miao J, Furuya T, Fan Q, Li X, Rathod P K, Su X Z and Cui L 2008 *Eukaryotic Cell* **7** 1200
15. Sbardella G, Castellano S, Vicidomini C, Rotili D, Nebbioso A, Miceli M, Altucci L and Mai A 2008 *Bioorg. Med. Chem. Lett.* **18** 2788
16. Rybak M J and Akins R L 2001 *Drugs* **61**, 1
17. Lipsitch M 2001 *Trends Microbiol.* **9** 438
18. Cunha B A 1998 *Drugs Today* **34** 691
19. Marchese A, Schito G C and Debbia E A 2000 *J. Chemother., (Firenze)* **12** 459
20. Cetinkaya Y, Falk P and Mayhall C G 2000 *Clin. Microbiol. Rev.* **13** 686
21. Cassell G H and Mekalanos J 2001 *J. Am. Med. Assoc.* **285** 601
22. Chu D T W, Plattner J J and Katz L 1996 *J. Med. Chem.* **39** 3853
23. Gulati A S and Subba Rao B C 1964 *Indian J. Chem.* **2** 337
24. EI Sholy M A, Adawadkar P D, Benigni D A, Watson E S and Little T L Jr. 1986 *J. Med. Chem.* **29** 606
25. (a) Dos Santos M L and de Magalhães G C 1993 *Quim Nova*, **16**, 534; (b) Carvalho M G, Braz-Filho R, Dos Santos M L and de Magalhães G C 1993 *J. Braz. Chem. Soc.* **4** 158; (c) Dos Santos M L and de Magalhães 1999 *J. Braz. Chem. Soc.* **10** 13; (d) Lúcio P L Logrado, Dâmaris Silveira, Luiz A S Romeiro, Manoel O de Moraes, Bruno C Cavalcanti, Letícia V Costa-Lotufu, Cláudia do Ó Pessoa and Maria Lucilia dos Santos 2005 *J. Braz. Chem. Soc.* **16** 1217
26. (a) Kiong L S and Tyman J H P 1981 *J. Chem. Soc. Perkin Trans.* **1** 1942; (b) Paramashivappa R, Phanikumar P, Vithayathil P J and Srinivasa Rao A 2001 *J. Agric. Food Chem.* **49** 2548
27. Rahman A, Choudhary M I and Thomsen W J 2001 *Bioassay techniques for drug development* (The Netherlands: Harwood Academic Publishers) pp. 16